Desmopressin
Also known as: DDAVP, 1-deamino-8-D-arginine vasopressin, Minirin, Stimate
A synthetic vasopressin analog that regulates water reabsorption and is used clinically for diabetes insipidus, nocturnal enuresis, and hemophilia management.
Beginner Basics
Plain-English guide to Desmopressin
What it does
Desmopressin helps your body hold onto water by signaling kidneys to reabsorb it instead of releasing it as urine. Researchers use it to study water balance in the body and to manage excessive nighttime urination.
Typical dose
10-20 micrograms (mcg) once or twice daily, injected under the skin, though intranasal and oral forms exist with different dosing.
When to inject
Evening is typical for nighttime urination issues; morning and evening for managing water balance problems. Start with the lower dose and adjust based on response.
Storage
Keep the dry powder at room temperature away from light and moisture. Once mixed with liquid, store in the refrigerator and use within the timeframe specified by your supplier.
First-timer tip
Start at the low end of the dose range and increase slowly while monitoring how your body responds-this peptide affects fluid balance, so gradual adjustment is safer than jumping to higher doses.
On This Page
Research Status
FDA-approved
For research purposes only. Not approved for human use. Not medical advice.
Research Areas
Side Effects
Occurs when desmopressin-induced water reabsorption exceeds water intake, diluting serum sodium. Symptoms include headache, nausea, confusion, lethargy, seizures, and coma. Risk increases with excessive fluid intake, renal impairment, or SIADH. Requires immediate medical evaluation and serum sodium measurement. Fluid restriction is the primary management strategy.
Often mild and self-resolving. May be related to hyponatremia or local injection site effects. Monitor serum sodium if headaches persist or worsen.
Usually mild and transient. May occur within 1–2 hours of injection. Can be a sign of hyponatremia; monitor serum sodium if symptoms persist.
Mild gastrointestinal discomfort may occur, particularly with higher doses. Typically resolves within a few hours.
Transient facial flushing or warmth may occur due to mild vasodilation from V1 receptor activation. Self-resolving.
Mild erythema, swelling, or discomfort at the injection site. Prevented by proper site rotation and injection technique. Apply ice if needed.
Rare but possible; includes urticaria, angioedema, or anaphylaxis. Seek immediate medical attention if difficulty breathing, throat swelling, or severe rash occurs.
Severe hyponatremia with cerebral edema, seizures, and altered consciousness. Occurs with excessive desmopressin dosing and high fluid intake. Requires emergency medical intervention and fluid restriction.
Very rare; reported with high-dose desmopressin in patients with thrombotic risk factors. Monitor for signs of deep vein thrombosis or pulmonary embolism.
Dosing Reference
| Parameter | Value |
|---|---|
| Dose range | 10-20 mcg |
Frequency, timing and route - members only | |
Research disclaimer
Figures drawn from published research literature and community logs. Not clinical recommendations. Consult a qualified professional. Research use only.
Reconstitution Guide
Do not use saline or bacteriostatic saline, use only bacteriostatic water for reconstitution
Do not shake the vial vigorously; gentle swirling prevents peptide degradation
Discard immediately if the solution appears cloudy, discolored, or contains visible particles
Use within 30 days of reconstitution when stored at 2-8°C
Do not freeze the reconstituted solution; freezing may denature the peptide
Use the PeptideVolt reconstitution calculator for your exact concentration
Molecular and Pharmacological Data
| Molecular weight | 1069.2 |
| Half-life | 2.5 hours (subcutaneous); 1.5–2.5 hours (intranasal) |
| Sequence | Members only |
Desmopressin is a synthetic analog of vasopressin (antidiuretic hormone) that selectively activates V2 receptors on the principal cells of the kidney's collecting duct. This activation increases aquaporin-2 water channel expression and insertion into the apical membrane, enhancing water reabsorption and reducing urine output. It also has weak V1 receptor activity, which contributes to hemostatic effects by promoting von Willebrand factor and factor VIII release from endothelial cells.
Track your Desmopressin research
Free account. No credit card required.
Recent Research
Reduction of hemorrhagic complications after non-focal renal biopsy with pre-procedure desmopressin administration.
Use, efficacy, and safety of desmopressin for congenital nephrogenic diabetes insipidus in children: a nationwide survey.
Haemostasis and beyond: The expanding role of desmopressin in intensive care.
Source: PubMed / NCBI. Updated daily. Articles are listed for research reference only.
Browse the Research Library
40+ peptide profiles with mechanism summaries, dosing data, and reconstitution guides.
View all peptidesResearch Use Only. All content on this page is provided for informational and educational purposes related to scientific research. Desmopressin is not approved for human use by the FDA or any equivalent regulatory body. This is not medical advice. Do not use any substance discussed here for therapeutic, diagnostic, or preventative purposes. Consult a qualified healthcare professional before making any health-related decisions. The Peptide Volt does not endorse the use of any research chemicals. 18+ only.